Practical Assessment of Psoriasis Clinical Severity in both Clinical Trials and Clinical Practice Settings: A Report from the GRAPPA 2016 Annual Meeting

被引：2

作者：

Merola, Joseph F. ^{[1
]}

Gottlieb, Alice B. ^{[2
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol, Dept Dermatol & Med, 75 Francis St, Boston, MA 02115 USA

[2] New York Med Coll, Dermatol, Valhalla, NY 10595 USA

来源：

JOURNAL OF RHEUMATOLOGY | 2017年 / 44卷 / 05期

关键词：

PSORIATIC ARTHRITIS; PSORIASIS; COMBINED CLINIC; GRAPPA; EFFICACY; MODERATE; AREA;

D O I：

10.3899/jrheum.170147

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

At the 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), we presented the case for quantitatively assessing the extent of both psoriasis and psoriatic arthritis in the clinical setting, with a particular focus on the validation and expanded novel use of the PGAxBSA (static physician's global assessment x body surface area of involvement) in the era of targeted metrics. Herein, we summarize our presentation.

引用

页码：691 / 692

页数：2

共 50 条

[41] Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council
Strober, Bruce
van de Kerkhof, Peter C. M.
Duffin, Kristina Callis
Poulin, Yves
Warren, Richard B.
de la Cruz, Claudia
van der Walt, Joelle M.
Stolshek, Bradley S.
Martin, Mona L.
de Carvalho, Andre V. E.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (05) : 699 - 709
[42] Using Hawthorne Effects to Improve Adherence in Clinical Practice: Lessons From Clinical Trials
Davis, Scott A.
Feldman, Steven R.
JAMA DERMATOLOGY, 2013, 149 (04) : 490 - 491
[43] First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice
Pol, S.
Lampertico, P.
JOURNAL OF VIRAL HEPATITIS, 2012, 19 (06) : 377 - 386
[44] Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials
Nast, A.
Dilleen, M.
Liyanage, W.
Aikman, L.
Szczypa, P.
Dressler, C.
BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) : 400 - 405
[45] Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research
Gao, Yujie
Xu, Tianqi
Wang, Yu
Hu, Yanjinhui
Yin, Shaoping
Qin, Zhiguo
Yu, Hua
PHARMACEUTICS, 2025, 17 (01)
[46] Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab
Torii, Hideshi
Sato, Noriko
Yoshinari, Toru
Nakagawa, Hidemi
JOURNAL OF DERMATOLOGY, 2012, 39 (03) : 253 - 259
[47] The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study
Jullien, Denis
Richard, Marie-Aleth
Halioua, Bruno
Bessette, Christel
Derancourt, Christian
Bouloc, Anne
DERMATOLOGY AND THERAPY, 2023, 13 (06) : 1361 - 1376
[48] Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice
Striano, Pasquale
McMurray, Rob
Santamarina, Estevo
Falip, Merce
EPILEPTIC DISORDERS, 2018, 20 (01) : 13 - 29
[49] Adverse events from systemic therapies for psoriasis are common in clinical practice
Pearce, Daniel J.
Higgins, Kristen B.
Stealey, Katherine H.
Balkrishnan, Rajesh
Crane, Martin M.
Camacho, Fabian
Fleischer, Alan B., Jr.
Feldman, Steven R.
JOURNAL OF DERMATOLOGICAL TREATMENT, 2006, 17 (05) : 288 - 293
[50] Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials
Gordon, K. B.
Reich, K.
Crowley, J. J.
Korman, N. J.
Murphy, F. T.
Poulin, Y.
Spelman, L.
Yamauchi, P. S.
Mendelsohn, A. M.
Parno, J.
Rozzo, S. J.
Ellis, C. N.
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 219 - 228

← 1 2 3 4 5 →